About BioVie Inc.
https://bioviepharma.comBioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States.
CEO
Cuong Viet Do
Compensation Summary
(Year 2025)
Salary $618,000
Bonus $92,700
Option Awards $149,449
Total Compensation $860,149
Industry Biotechnology
Sector Healthcare
Went public September 18, 2020
Method of going public IPO
Full time employees 14
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-07 | Reverse | 1:10 |
| 2024-08-06 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 11
Showing Top 1 of 11
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 5
Overall Score 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
SWISSPARTNERS LTD.
Shares:294.35K
Value:$356.16K
AJ WEALTH STRATEGIES, LLC
Shares:23.47K
Value:$28.4K
BLACKROCK INC.
Shares:21.17K
Value:$25.62K
Summary
% Of Shares Owned 4.56%
Total Number Of Holders 16
Showing Top 3 of 16
Market Cap $9.80 M
52w High $22.90
52w Low $1.10
P/E -0.2
Volume 121.31K
Outstanding Shares 7.54M
About BioVie Inc.
https://bioviepharma.comBioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $5.23M ▲ | $-5.13M ▼ | 0% | $-0.98 ▼ | $-5.07M ▼ |
| Q4-2025 | $0 | $3.61M ▲ | $-3.49M ▼ | 0% | $0.98 ▲ | $-3.43M ▼ |
| Q3-2025 | $0 | $2.99M ▼ | $-2.79M ▲ | 0% | $-1.5 ▲ | $-2.93M ▲ |
| Q2-2025 | $0 | $7.29M ▲ | $-7.11M ▼ | 0% | $-4.6 ▲ | $-7.24M ▼ |
| Q1-2025 | $0 | $4.12M | $-4.15M | 0% | $-7 | $-4.06M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $24.98M ▲ | $26.82M ▲ | $1.9M ▼ | $24.92M ▲ |
| Q4-2025 | $17.54M ▼ | $21.56M ▼ | $2.55M ▼ | $19.01M ▼ |
| Q3-2025 | $23.15M ▼ | $24.66M ▼ | $2.84M ▲ | $21.82M ▼ |
| Q2-2025 | $24.41M ▲ | $25.69M ▲ | $1.77M ▼ | $23.92M ▲ |
| Q1-2025 | $20.02M | $21.24M | $7.17M | $14.07M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-5.09M ▼ | $-3.02M ▲ | $0 | $10.46M ▲ | $7.43M ▲ | $-3.02M ▲ |
| Q4-2025 | $-3.49M ▼ | $-5.61M ▼ | $0 | $0 | $-5.61M ▼ | $-5.61M ▼ |
| Q3-2025 | $-2.79M ▲ | $-1.25M ▲ | $0 | $0 ▼ | $-1.25M ▼ | $-1.25M ▲ |
| Q2-2025 | $-7.11M ▼ | $-8.58M ▼ | $0 | $12.97M ▲ | $4.38M ▲ | $-8.58M ▼ |
| Q1-2025 | $-4.15M | $-3.58M | $0 | $-240.94K | $-3.82M | $-3.58M |
CEO
Cuong Viet Do
Compensation Summary
(Year 2025)
Salary $618,000
Bonus $92,700
Option Awards $149,449
Total Compensation $860,149
Industry Biotechnology
Sector Healthcare
Went public September 18, 2020
Method of going public IPO
Full time employees 14
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-07 | Reverse | 1:10 |
| 2024-08-06 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 11
Showing Top 1 of 11
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 5
Overall Score 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
SWISSPARTNERS LTD.
Shares:294.35K
Value:$356.16K
AJ WEALTH STRATEGIES, LLC
Shares:23.47K
Value:$28.4K
BLACKROCK INC.
Shares:21.17K
Value:$25.62K
Summary
% Of Shares Owned 4.56%
Total Number Of Holders 16
Showing Top 3 of 16